Form 4 Filing for Thomas J. Lynch Jr. - Foghorn Therapeutics Inc.

Thomas J. Lynch Jr., a director at Foghorn Therapeutics Inc., was granted 28,000 stock options on June 24, 2026. These options, with an exercise price of $4.08 per share, vest in full on the first anniversary of the grant date, contingent upon continued service on the board. The options are exercisable for Foghorn Therapeutics Inc. Common Stock and expire on June 23, 2036. This transaction is reported on Form 4, with the signature date of June 25, 2026.